A single nighttime dose of ranitidine 300 mg versus ranitidine 150 mg twice daily in the acute treatment of duodenal ulcer: a European multicenter trial. 1986

B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers

Six hundred and five patients with endoscopically diagnosed duodenal ulcer were randomly allocated to treatment with ranitidine 300 mg at night or ranitidine 150 mg twice daily in a prospective double-blind multicenter trial conducted in nine European countries. Endoscopy at 4 weeks showed complete ulcer healing in 246 of 301 patients (82%) treated with ranitidine 150 mg b.i.d. and 230 of 304 patients (76%) treated with ranitidine 300 mg at night. Cumulative healing rates at 8 weeks were 95 and 94% respectively. Both treatment regimens were equally effective at rapidly reducing the incidence of ulcer-related symptoms. Adverse events were few and consistent with those reported in previous studies with ranitidine 150 mg twice daily. The results of this trial indicate that a single nighttime dose of ranitidine is an effective and safe alternative to the twice daily regimen in the acute treatment of duodenal ulcer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005260 Female Females

Related Publications

B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
April 1988, The Journal of the Association of Physicians of India,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
September 1985, The American journal of gastroenterology,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
September 1986, Gut,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
August 1984, Lancet (London, England),
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
September 1986, Scandinavian journal of gastroenterology,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
July 1989, Fortschritte der Medizin,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
January 1993, Acta gastroenterologica Latinoamericana,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
January 1989, Revista do Hospital das Clinicas,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
July 1986, International journal of clinical pharmacology, therapy, and toxicology,
B Simon, and G Bianchi Porro, and M Cremer, and G Dobrilla, and U Haglund, and S L Dunn, and K Summers
April 1989, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!